A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features

@article{Rothschild2004ADR,
  title={A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features},
  author={Anthony J. Rothschild and Douglas J. Williamson and Mauricio Tohen and Alan Schatzberg and Scott W. Andersen and Luann E Van Campen and Todd M. Sanger and Gary D. Tollefson},
  journal={Journal of Clinical Psychopharmacology},
  year={2004},
  volume={24},
  pages={365-373}
}
Abstract: The purpose of this study was to compare the efficacy and safety of olanzapine (OLZ) monotherapy and an olanzapine/fluoxetine combination (OFC) with placebo (PLA) for unipolar major depression with psychotic features. Under a single protocol, two 8-week, double-blind trials were conducted at 27 sites. Patients (n = 124 trial 1, n = 125 trial 2) were randomized to 1 of 3 treatment groups: OLZ (5 to 20 mg/d), PLA, or OFC (olanzapine 5 to 20 mg/d + fluoxetine 20 to 80 mg/d). The primary… Expand
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
TLDR
The olanzapine/fluoxetine combination did not differ significantly from the other therapies at endpoint, although it demonstrated a more rapid response that was sustained until the end of treatment. Expand
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).
TLDR
Combination pharmacotherapy is efficacious for the treatment of MD with psychotic features and future research must determine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 weeks. Expand
A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression
TLDR
The OFC had a safety profile comparable to its component monotherapies, showed a rapid onset of antidepressant effect, and was effective in this TRD sample. Expand
Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression
TLDR
Analysis of data collected in a multi-site, randomized, placebo-controlled trial of patients with psychotic depression found that inpatient entry status, olanzapine monotherapy, and higher cumulative medical burden were statistically significant independent predictors of overall non-completion. Expand
Olanzapine in the treatment of depression with psychotic features: A prospective open-label study
TLDR
Olanzapine is effective and tolerable in combination with an antidepressant in an MDDp inpatient sample, and concur with data supporting good efficacy in negative and depressive symptoms of patients with schizophrenic and schizoaffective diseases. Expand
Quetiapine in combination with citalopram in patients with unipolar psychotic depression
TLDR
Quetiapine in combination with citalopram appears to be effective and well tolerated in the treatment of unipolar psychotic depression and further studies of larger, double-blind, parallel-group design are warranted to confirm these findings. Expand
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
  • S. Dodd, M. Berk
  • Psychology, Medicine
  • Expert review of neurotherapeutics
  • 2008
TLDR
Treatment using olanzapine/fluoxetine combination (OFC) is one of many options and has been associated with some side effects, including weight gain and the metabolic syndrome, somnolence, dry mouth, increased appetite and headache. Expand
An Open Study of Aripiprazole and Escitalopram for Psychotic Major Depressive Disorder
TLDR
The combination of escitalopram and aripiprazole seems to be an effective and safe treatment for MD-Psy. Expand
Aripiprazole versus haloperidol treatment in early-stage schizophrenia.
TLDR
Aripiprazole has a favorable efficacy/safety profile in ESS and appeared to be superior to haloperidol on a number of efficacy and safety outcomes, however, excessive dosing of the antipsychotic medications, in particular hal operidol, may have played an important role in accounting for the differences. Expand
Weight gain during olanzapine treatment for psychotic depression: effects of dose and age
TLDR
Age was observed to have a significant negative association with weight gain (P=0.01), even after controlling for differences in cumulative dose and baseline body mass index, and cumulative olanzapine dose was also significantly associated with weightgain. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
TLDR
Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated. Expand
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
TLDR
Fluoxetine when used in combination with perphenazine for the treatment of patients with psychotic depression has a response rate similar to the reported rates of response for tricyclic antidepressants, TCA plus antipsychotics, amoxapine, and electroconvulsive therapy. Expand
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
TLDR
Olanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder. Expand
Olanzapine: an updated review of its use in the management of schizophrenia.
TLDR
Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in thetreatment of some patients with first-episode or treatment-resistant schizophrenia. Expand
Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
TLDR
The results of this pilot double-blind trial show that fluvoxamine is useful in the treatment of delusional depression and suggest that venlafaxine may also be an effective compound in the Treatment of this disorder. Expand
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
TLDR
The results of this trial suggest that the therapeutic effect of HAL/AMI is superior to RIS in the total group of patients with combined psychotic and depressive symptoms, but subgroup differences have to be considered. Expand
Olanzapine response in psychotic depression.
TLDR
Olanzapine appears to be effective and safe for patients with psychotic depression and its unique pharmacologic profile may make it particularly useful for the treatment of psychotic depression either alone or in combination with antidepressants. Expand
Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex
TLDR
The large, sustained increase of [DA]ex, [NE)ex, and [5-HT]ex in PFC after olanzapine-fluoxetine treatment was unique and may contribute to the profound antidepressive effect of the olanZapine and fluoxettine therapy in TRD. Expand
Management of psychotic, treatment-resistant depression.
  • A. Rothschild
  • Psychology, Medicine
  • The Psychiatric clinics of North America
  • 1996
TLDR
The answers to these questions would provide clinicians with important tools to treat patients with psychotic depression, an illness that all too frequently can become treatment-resistant. Expand
Long‐term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study
TLDR
Fluvoxamine might be a promising drug for long-term therapy of delusional depression and further controlled studies are required to confirm this finding. Expand
...
1
2
3
4
...